%0 Journal Article
%@ 0036-5548
%A  Gönczöl Éva
%A  Berencsi Klára
%A  Kauffman Elizabeth
%A  Endrész Valéria
%A  Pincus Steven
%A  Cox William
%A  Meric Claude
%A  Paoletti Enzo
%A  Plotkin Stanley A.
%A Orvosi Mikrobiológiai és Immunbiológiai Intézet SZTE / ÁOK OMII [2002-2021],
%D 1996
%F publicatio:31774
%J SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
%N Suppl.
%P 110-112
%T Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate; immune response elicited in a prime/boost protocol with the glycoprotein B subunit
%U http://publicatio.bibl.u-szeged.hu/31774/
%V 99
%X A canarypox glycoprotein B (ALVAC-gB) recombinant induces human cytomegalovirus-specific neutralizing antibodies and a gB-specific cytotoxic T-lymphocyte response. The priming effect of ALVAC-gB is more efficient than that of the gB subunit in Al(OH)3. Antibodies of IgG2a isotype are induced by ALVAC-gB.